FDA approves AZ's Btk inhibitor Calquence for MCL

FDA granted accelerated approval to Calquence acalabrutinib (formerly ACP-196) from AstraZeneca plc (LSE:AZN; NYSE:AZN) and Acerta Pharma B.V. (Oss, the Netherlands) to

Read the full 228 word article

User Sign In